Update on COVID-19
* Update valid as of 28th September 2020
- Number of tests: 45855
- Results received: 45824
- Results pending:31
- Confirmed cases: 382
- Recovered cases:341
- Active cases in Gibraltar*: 38 (38 residents, 0 visitors)
* Active cases refer to those who have tested positive for COVID-19 and have not yet been deemed clinically recovered/ Covid-free by a clinician.
- No. in self-isolation:292
- Deaths: 0
For previous Gibraltar statistics, click here.
*Please look out for updates on the Pop Up swabbing stations.
- Self isolation and Testing Requirements for Travellers from ‘Relevant Areas’
- Changes to Golden Hour and Silver Time
- COVID-19 Travel Considerations (eg. flights, tests and certificates)
- Young people must protect their families from COVID-19
- Let’s Beat Covid Together – get the app for your mobile phone
- Update and advice for visitors to St Bernard’s Hospital.
- Shielding to protect the vulnerable
- Information for Close Contacts- Contact Tracing Guidance
- General Guidance for Workplaces and Businesses
If you live in Spain and want to further information on COVID-19, see Junta de Andalucia.
Over 30 million cases of COVID-19 and over 950,000 deaths have now been reported to WHO.
For the latest WHO situation report and global statistics, see here.
WHO is working in collaboration with scientists, business, and global health organizations through the ACT Accelerator to speed up the pandemic response. 172 economies are currently engaged in discussions to potentially participate in COVAX, a global initiative aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines, once they are licensed and approved.
COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.
The goal of COVAX is to deliver two billion doses of safe, effective vaccines that have passed regulatory approval and/or WHO prequalification by the end of 2021. Read more.